Track BioCryst Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BioCryst Pharmaceuticals, Inc. BCRX · Stock Open BioCryst Pharmaceuticals, Inc. in new tab

7.61 USD
P/E
7.60
EPS
-1.28
P/B
-4.90
Beta
0.51
Target Price
20.45 USD
BioCryst Pharmaceuticals, Inc. logo

BioCryst Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2026

BioCryst shares fell 3.9% after earnings, with the likely concern that the quarter’s revenue included an upper-teens-of-millions contribution from CareMed’s one-time inventory build, making reported growth less representative of underlying demand. The company said ORLADEYO revenue excluding Europe still grew year over year after removing that benefit, but future revenue should more closely reflect patient demand.

  • Net revenue was $174.8 million in the quarter, with more than 95% from the U.S. business.
  • ORLADEYO revenue excluding Europe increased 20% year over year on a comparable basis; the CareMed inventory build contributed an upper-teens-of-millions amount to quarterly revenue.
  • CareMed’s inventory is expected to remain near the lower end of its typical 1-to-3-week range, limiting that transition-related revenue contribution going forward. BioCryst said days to first shipment for new patients are already improving.
  • Management reported continued growth in treated patients and new prescribers, and said early uptake of ORLADEYO pellets in children has been promising.
  • Navenibart’s pivotal trial fully enrolled in June, with 12-month top-line data still expected in the third quarter of next year; early BCX1777 data are expected by year-end.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E7.60
EPS-1.28
Book Value-1.55
Price to Book-4.90
% Insiders3.349%
Growth
Revenue Growth0.13%
Earnings Growth1.33%
Estimates
Forward P/E8.90
Forward EPS0.86
Target Mean Price20.45

DCF valuation

Model fair value for BioCryst Pharmaceuticals, Inc. (BCRX)
Result
Sign in to run the valuation for BCRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Buy · mean target 20.45 USD (low 11.00, high 32.00) · as of 15 Nov 2026
Low 11.00
Mean 20.45
High 32.00
Price 7.61
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

BioCryst Pharmaceuticals, Inc. Logo BioCryst Pharmaceuticals, Inc. Analysis (BCRX)

United States Health Care Official Website Stock

Is BioCryst Pharmaceuticals, Inc. a good investment? BioCryst Pharmaceuticals, Inc. (BCRX) is currently trading at 7.61 USD. Market analysts have a consensus price target of 20.45 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 7.60. This relatively low multiple may signal that BioCryst Pharmaceuticals, Inc. is undervalued compared to historical market norms.

Earnings Schedule: BioCryst Pharmaceuticals, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 0.86.

Investor FAQ

Does BioCryst Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is BioCryst Pharmaceuticals, Inc.?

BioCryst Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -1.28.

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Exchange Ticker
NMS (United States) BCRX
FRA (Germany) BO1.F
MEX (Mexico) BCRX.MX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion